On May 15th, the broader market experienced a deep correction. Hong Kong Stock Connect innovative drug stocks continued their decline, with leading heavyweights such as
For the week, the Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection ETF (520880) accumulated a loss of 6.91%, also closing its fourth consecutive weekly decline. However, trading activity was notably active, with weekly cumulative turnover reaching 2.004 billion yuan, a significant increase of nearly 60% compared to the previous week.
Analysis suggests that the recent accelerated decline in the Hong Kong Stock Connect innovative drug sector is primarily driven by capital flow and sentiment factors. On one hand, the siphon effect of the AI and technology thematic sectors has led to a significant diversion of liquidity. On the other hand, recent clinical data from certain individual innovative drug companies failing to meet expectations has heightened market sensitivity to R&D uncertainties.
Notably, long-term capital has begun accelerating its accumulation. As of May 14th, the Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection ETF (520880) has seen a net subscription exceeding 535 million yuan over the past 10 days. The fund's share count has also risen correspondingly, reaching a new high of 5.342 billion shares!
The firm capital inflows against the trend may stem from three robust fundamental supports for the innovative drug sector. First, outbound business development (BD) continues strong growth: total out-licensing transaction value for Chinese innovative drugs in Q1 2026 has already exceeded 60 billion USD. Second, policy support is clear: following accelerated inclusion of innovative drugs in the national reimbursement drug list, the "Implementation Measures for the Protection of Pharmaceutical Trial Data" has been issued and implemented, granting a 6-year protection period for trial data of innovative and original drugs. Third, the industry is entering a phase of self-sustainability: a batch of leading innovative drug companies are reaching their profitability inflection points.
Looking ahead, Industrial Securities notes that the innovative drug sector is about to enter a period of intensive data catalysts. The 2026 ASCO (American Society of Clinical Oncology) Annual Meeting is scheduled for May 29th to June 3rd, where several Chinese innovative drug companies are expected to release important clinical data, potentially catalyzing sector performance.
The current correction in the innovative drug sector has lasted for eight months, highlighting the prominent investment value at current levels. For accumulating core innovative drug assets at low levels, two key investment tools are recognized: For pure-play innovative drug exposure, consider the Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection ETF (520880), which invests 100% in innovative drug R&D companies. Its top ten holdings account for over 70% of the portfolio, highlighting its leading stock concentration. The underlying assets are Hong Kong-listed stocks, offering high elasticity and T+0 trading. For investors seeking to reduce volatility, the unique Huabao Pharmaceutical ETF (562050) is an option. Its exclusive allocation of "70% innovative drugs + 30% traditional Chinese medicine" is a scarce offering in the market, combining the high growth potential of innovative drugs with the high dividend characteristics of traditional Chinese medicine.
Note: According to data from the Shanghai and Shenzhen Stock Exchanges, as of the current date, the Huabao Pharmaceutical ETF is the only ETF in the market tracking the CSI Pharmaceutical Index. Note: ETF funds do not charge a sales service fee. When investors subscribe for or redeem fund shares, the subscription/redemption agent brokerage may charge a commission of up to 0.5%, which includes relevant fees charged by the stock exchanges and registration institutions. Please refer to each fund's legal documents for detailed fee information. Risk Disclosure: The index constituents mentioned are for illustrative purposes only. Descriptions of individual stocks do not constitute any form of investment advice nor represent the holdings information or trading动向 of any fund managed by the fund manager. The fund manager assesses the risk rating of the Huabao Pharmaceutical ETF and its feeder fund as R3-Medium Risk, suitable for Balanced (C3) and above investors. The risk rating of the Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection ETF and its feeder fund is assessed as R4-Medium to High Risk, suitable for Aggressive (C4) and above investors. Any information appearing in this article (including but not limited to individual stocks, commentary, forecasts, charts, indicators, theories, and any form of expression) is for reference only. Investors are responsible for their own investment decisions. Furthermore, any views, analyses, or forecasts herein do not constitute investment advice of any kind to the reader, and no responsibility is accepted for any direct or indirect losses arising from the use of this content. The performance of other funds managed by the fund manager does not guarantee the performance of this fund. Past performance of a fund is not indicative of its future performance. Fund investment carries risks.
Comments